Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2025 07:00 ET | Source: Charm Therapeutics

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...
September 02, 2025 02:00 ET | Source: Charm Therapeutics

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...
April 30, 2024 07:00 ET | Source: Charm Therapeutics

CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development

PRESS RELEASE CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development LONDON – 30 April 2024 -- CHARM Therapeutics (“CHARM”, “The Company”),...